Jubilant Ingrevia Q2 FY27 Revenue up 24% to ₹1,394 Crore, EBITDA up 51%
Jubilant Ingrevia reported Q2 FY27 revenue of ₹1,394 crore (up 24% YoY) and EBITDA of ₹221 crore (up 51% YoY). The company is acquiring a 40% stake in ZettaOne Technologies for ₹189.2 crore, entering the EDMS space. Management expressed confidence in sustained growth across all segments.
The significant growth in key financial metrics (revenue and EBITDA) and the strategic acquisition in a new sector are material events that will likely have a substantial impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with positive commentary from management about strategic execution and future outlook. The acquisition of ZettaOne also indicates a positive strategic expansion.
Jubilant Ingrevia Limited announced strong financial results for the quarter and half-year ended September 30, 2026. The company reported a 24% year-on-year increase in total revenue to ₹1,394 crore and a 51% year-on-year rise in EBITDA to ₹221 crore for Q2 FY27. For the half-year ended H1 FY27, revenue grew by 25% to ₹2,695 crore, and EBITDA increased by 44% to ₹431 crore. Profit After Tax (PAT) also saw significant growth, rising by 61% to ₹111 crore in Q2 FY27 and by 50% to ₹217 crore in H1 FY27.
The company's performance was driven by sustained growth across its business segments. Specialty Chemicals reported a 16% year-on-year revenue increase to ₹560 crore, with EBITDA growing by 12% to ₹140 crore. The Nutrition & Health Solutions segment saw a substantial 50% revenue jump to ₹270 crore and an 87% EBITDA increase to ₹39 crore. Chemical Intermediates revenue grew by 24% to ₹563 crore, with EBITDA surging by 226% to ₹64 crore.
In a strategic move, Jubilant Ingrevia has signed an agreement to acquire a 40% stake in ZettaOne Technologies Limited for ₹189.2 crore. This acquisition marks the company's entry into the Electronics Development and Manufacturing Services (EDMS) space, aiming to offer an integrated value proposition in the electronics and semiconductor sectors. ZettaOne is expected to grow by 60-70% in FY27.
Management commentary highlighted disciplined execution, successful implementation of the Pinnacle strategy, and robust cost management as key drivers for the strong performance. The company expressed confidence in sustaining this momentum, with growth anticipated across all business segments in FY27. The new Multi-Purpose Plant is on track for commissioning by year-end, further strengthening the CDMO and Fine Chemicals roadmap. The company also announced an investors' conference call scheduled for October 27, 2026, at 5:00 PM IST to discuss the results.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.